EUVIMEDEUVIMED entdecken
Open Access

Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials

Julia Blanter iD, Grace Van Hyfte, Maham Ahmad, Suzanne Xu, Olivia Hapanowicz, Gabriela Fazilov iD, Ashley Lu iD, Natalie Lucas, Kathy Wu iD, Gary Shelton, Mandy DeMerchant, Michael Lachowicz und 9 weitere

JCO Oncology Practice · 2025-06 · 21 (6) · 862-875

DOI: 10.1200/op.24.00293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2025-06. Verfasst von Julia Blanter und 20 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Financial toxicity (FT) adversely influences patient quality of life and is a barrier to clinical trial enrollment. Early-phase clinical trials (EPCTs) recruit patients who may have high baseline FT and require additional visits and procedures, potentially increasing FT. METHODS In this prospective survey study, we sought to assess FT at baseline and after 2 months among patients with advanced solid malignancies participating in EPCTs. Participants were age 18 years and older, were English-speaking, and were treated at the Yale Cancer Center (Yale) and the Tisch Cancer Institute at Mount Sinai (Mount Sinai). At the time of consent and 2 months later, patients completed a sociodemographic questionnaire as well as the 11-item validated Comprehensive Score for Financial Toxicity (COST) instrument. Primary outcomes were baseline COST score and change in COST score from baseline to 2 months. Lower score is associated with higher FT. RESULTS One hundred forty-six patients completed survey 1. Mean age was 61.5 years and 50.7% were male. The most common histologies were lung (17.8%), colorectal (16.4%), and breast (12.3%) cancers. Mean baseline COST score was 22.12 (standard deviation, 8.01). FT was associated with being a primary wage earner ( P = .044) and inversely associated with age ( P = .025). Seventy-one patients completed survey 2. Among 71 patients who completed both surveys, there was no significant difference in COST score between surveys 1 and 2 ( P = .28). Race, ethnicity, education, and household income were not associated with baseline COST score or change in FT. CONCLUSION Moderate FT was reported at baseline and on trial among EPCT participants. No change in FT was observed between time points. Additional efforts should be made to decrease FT associated with EPCT participation to maximize access to novel therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsClinical Trials as TopicHumansMaleFemaleMiddle AgedAgedProspective StudiesSurveys and QuestionnairesQuality of LifeAdult

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, New York, NY.
  • Yale University School of Medicine, New Haven, CT.
  • Johns Hopkins School of Medicine, Baltimore, MD.
  • Yale Cancer Center, New Haven, CT.
  • Arvinas, Inc.
  • Zucker School of Medicine at Hofstra/Northwell Health, New Hyde Park, NY.

ORCID-Profile: Julia Blanter, Gabriela Fazilov, Ashley Lu, Kathy Wu, Melanie Kier, Joseph P Eder, Matthew D Galsky, Thomas U Marron, Cardinale B Smith, Deborah B Doroshow

Förderung

  • NCI NIH HHS

Zitieren

APA

Blanter, J., Van Hyfte, G., Ahmad, M., Xu, S., Hapanowicz, O., Fazilov, G., Lu, A., Lucas, N., Wu, K., Shelton, G., DeMerchant, M., Lachowicz, M., Kier, M., Werner, M., Eder, J. P., Galsky, M. D., Marron, T. U., Smith, C. B., LoRusso, P. M., …, & Doroshow, D. B. (2025). Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials. JCO Oncology Practice, 21(6), 862-875. https://doi.org/10.1200/op.24.00293

Vancouver

Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, et al. Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials. JCO Oncology Practice. 2025;21(6):862-875. doi:10.1200/op.24.00293

BibTeX
@article{Blanter2025,
  author = {Blanter, Julia and Van Hyfte, Grace and Ahmad, Maham and Xu, Suzanne and Hapanowicz, Olivia and Fazilov, Gabriela and Lu, Ashley and Lucas, Natalie and Wu, Kathy and Shelton, Gary and DeMerchant, Mandy and Lachowicz, Michael and Kier, Melanie and Werner, Michael and Eder, Joseph P and Galsky, Matthew D and Marron, Thomas U and Smith, Cardinale B and LoRusso, Patricia M and Hofstatter, Erin and Doroshow, Deborah B},
  title = {Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials},
  journal = {JCO Oncology Practice},
  year = {2025},
  volume = {21},
  number = {6},
  pages = {862--875},
  doi = {10.1200/op.24.00293}
}
Kostenlos starten →